Results Snapshot
Quarterly Analysis Highlights - YoY
Net Sales
YoY Growth in quarter ended Sep 2026 is 362.45% vs -72.74% in Sep 2025
Standalone Net Profit
YoY Growth in quarter ended Sep 2026 is 108.17% vs -845.45% in Sep 2025
Operating Profit (PBDIT) excl Other Income
YoY Growth in quarter ended Sep 2026 is 14.47% vs -895.00% in Sep 2025
Interest
YoY Growth in quarter ended Sep 2026 is -4.17% vs 84.62% in Sep 2025
Operating Profit Margin (Excl OI)
YoY Growth in quarter ended Sep 2026 has improved from Sep 2025
Compare Quarterly Results Of Parmax Pharma With
Quarterly - Net Sales
QoQ Growth in quarter ended Sep 2026 is 42.34% vs 148.34% in Jun 2026
YoY Growth in quarter ended Sep 2026 is 362.45% vs -72.74% in Sep 2025
Quarterly - Standalone Net Profit
QoQ Growth in quarter ended Sep 2026 is -92.27% vs 479.31% in Jun 2026
YoY Growth in quarter ended Sep 2026 is 108.17% vs -845.45% in Sep 2025
Quarterly - Operating Profit (PBDIT)
QoQ Growth in quarter ended Sep 2026 is -263.86% vs 153.55% in Jun 2026
YoY Growth in quarter ended Sep 2026 is 14.47% vs -895.00% in Sep 2025
Quarterly - Interest
QoQ Growth in quarter ended Sep 2026 is 0.00% vs -54.00% in Jun 2026
YoY Growth in quarter ended Sep 2026 is -4.17% vs 84.62% in Sep 2025
Quarterly - Operating Profit Margin (Excl OI)
QoQ Growth in quarter ended Sep 2026 has fallen from Jun 2026
YoY Growth in quarter ended Sep 2026 has improved from Sep 2025